Here are five observations:
1. Among other findings in the report, which ran 121 pages, Theranos used unqualified or inadequately trained personnel and stored samples in freezers that were not at the proper temperature. It also failed to ensure that the quality control for an important blood-clotting test was acceptable before reporting results for patients.
2. The report is from an inspection last fall of Theranos’ laboratory in Newark, Calif., by CMS.
3. Earlier this week, researchers at the Icahn School of Medicine at Mount Sinai in New York City published the first independent assessment of Theranos, finding that it produced more irregular results than two more conventional laboratories.
4. Some of the most serious findings involve a test of blood clotting used on patients who take the blood thinner warfarin.
5. Theranos is a privately held health technology and medical-laboratory services company based in Palo Alto, Calif.
More articles on quality & infection control:
5 things to know about American Pain Society’s postsurgical pain management guideline
5 sample OR/procedure room cleaning checklists
New patient safety report highlights physicians’ bad behavior — 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.